CClinicalTrials.gg
Active, not recruitingNCT01936272Updated May 18, 2026

Randomized Controlled Trial of Shunt vs ETV/CPC for PIH in Ugandan Infants

A Phase 3 interventional study of Chhabra Shunt Placement and ETV/CPC in Hydrocephalus, sponsored by Boston Children's Hospital. Active, not recruiting at 1 site in Uganda. Open to participants aged 1 Day to 180 Days. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Boston Children's Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Day to 180 Days
Sex
All
01

Study summary

Two treatment options exist for infant patients with hydrocephalus. Most patients are treated with a surgical procedure in which a shunt is inserted into the brain and abdomen. In recent years, however, another treatment has developed called Endoscopic Third Ventriculostomy (ETV) with Choroid Plexus Cauterization (ETV/CPC).This research study is being done to measure the results of these procedures in children less than six months of age who have hydrocephalus as the result of a brain infection, called post-infectious hydrocephalus, or PIH. This study will evaluate patients in more detail to measure brain growth and development.

Read the detailed description

World over, infants with hydrocephalus are mainly treated using a shunt, which is a device made of soft plastic tubing that moves extra fluid from the brain to the abdomen. Surgery is required to insert a shunt into the brain and the abdomen. In recent years, we have developed another treatment called Endoscopic Third Ventriculostomy (ETV) with Choroid Plexus Cauterization (ETV/CPC). This research study is being done to measure the results of these procedures in children less than six months of age who have hydrocephalus as the result of a brain infection, called post-infectious hydrocephalus, or PIH. This is the most common cause of hydrocephalus in Ugandan babies. This study will evaluate patients in more detail to measure brain growth and development. Children in the study will have special testing to measure developmental progress as well as special imaging to evaluate the progress of their brain growth.

02

Conditions studied

  • Hydrocephalus

Browse trials for

03

In context

Hydrocephalus

210 studies on the registry are indexed under Hydrocephalus; 51 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 105 interventional studies indexed under Hydrocephalus.

Browse Hydrocephalus studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 180 Days
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Infants less than 180 days (six months) old
  • Symptomatic hydrocephalus
  • Post-infectious Hydrocephalus based on clinical and CT parameters2
  • Must be from the following Ugandan districts: Bugiri, Busia, Iganga, Jinja, Kampala, Kamuli, Kapchorwa, Katakwi, Kumi, Mayuge, Mbale, Mukono, Pallisa, Sironko, Soroti, and Tororo

Exclusion criteria

Exclusion Criteria:

  • Any patient with a scalp erosion or infection that would exclude the patient from shunt implantation
  • Any patient with ventricular loculations that would normally indicate the use of ventriculoscopy as an adjunct to shunt placement
  • Any patient with absence of any visible cortical mantle on the CT
  • Patients must be appropriate candidates for either surgical procedure - shunt placement alone or ETV/CPC
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Chhabra Shunt Placement

    The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.

    Device: Chhabra Shunt Placement

  • Active comparator
    ETV/CPC

    The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.

    Procedure: ETV/CPC

Interventions

  • DeviceChhabra Shunt Placement
  • ProcedureETV/CPC
06

What researchers measure

Primary outcomes

  1. Change of Age-normed Bayley Scales of Infant Development (BSID)-III scores

    Neurocognition will be measured using the BSID-III Cognitive Scale. Change will be assessed at 24 months post treatment from baseline score (12 months post treatment).

    Time frame: 12 months and 24 months post treatment

Secondary outcomes

  1. Brain Volume

    Volume unit of measure is cubic millimeters. Volume is measured using CT scans.

    Time frame: 12 months, 24 months, 5 years, and 7-10 years post treatment

  2. CSF Volume

    Volume unit of measure is cubic millimeters. Volume is measured using CT scans.

    Time frame: 12 months, 24 months, 5 years, and 7-10 years post treatment

  3. Vineland Adaptive Behavior Scales

    The primary purpose of the VABS is to assess the social abilities of school age children.

    Time frame: 5 years and 7-10 years post treatment

07

Study locations

1 site
  • CURE Children's Hospital Uganda
    Mbale, Uganda
08

References and documents

Publications

  • Harper JR, Cherukuri V, O'Reilly T, Yu M, Mbabazi-Kabachelor E, Mulando R, Sheth KN, Webb AG, Warf BC, Kulkarni AV, Monga V, Schiff SJ. Assessing the utility of low resolution brain imaging: treatment of infant hydrocephalus. Neuroimage Clin. 2021;32:102896. doi: 10.1016/j.nicl.2021.102896. Epub 2021 Nov 23. PubMed 34911199 ↗
  • Punchak M, Mbabazi Kabachelor E, Ogwal M, Nalule E, Nalwoga J, Ssenyonga P, Mugamba J, Rattani A, Dewan MC, Kulkarni AV, Schiff SJ, Warf B. The Incidence of Postoperative Seizures Following Treatment of Postinfectious Hydrocephalus in Ugandan Infants: A Post Hoc Comparison of Endoscopic Treatment vs Shunt Placement in a Randomized Controlled Trial. Neurosurgery. 2019 Oct 1;85(4):E714-E721. doi: 10.1093/neuros/nyz122. PubMed 31086941 ↗
  • Kulkarni AV, Schiff SJ, Mbabazi-Kabachelor E, Mugamba J, Ssenyonga P, Donnelly R, Levenbach J, Monga V, Peterson M, MacDonald M, Cherukuri V, Warf BC. Endoscopic Treatment versus Shunting for Infant Hydrocephalus in Uganda. N Engl J Med. 2017 Dec 21;377(25):2456-2464. doi: 10.1056/NEJMoa1707568. PubMed 29262276 ↗

Individual participant data

Plan to share: No — IPD will not be shared with researchers outside of the study team.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01936272
Lead sponsor
Boston Children's Hospital
Collaborators
Penn State University, The Hospital for Sick Children, CURE Children's Hospital, Uganda
Responsible party
Benjamin C. Warf (Professor of Neurosurgery, Hydrocephalus and Spina Bifida Chair, Boston Children's Hospital) — Principal investigator
First posted
Sep 6, 2013
Start date
May 27, 2013
Primary completion
Jun 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
May 18, 2026

Study contacts

Benjamin C Warf, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion